{"role": "assistant", "content": null, "function_call": {"name": "get_risks", "arguments": "{\"risks\":[{\"Description\":\"Investigation of new drugs for COVID-19 therapy, such as tocilizumab and ACE2-targeted treatments, may have unknown side effects and long-term impacts.\",\"Impact\":\"Potential for unforeseen adverse effects on patients, including new health complications and exacerbation of existing conditions.\",\"Mitigation\":\"Thorough clinical trials, post-marketing surveillance, and rigorous monitoring of patient outcomes to identify and address any adverse effects.\",\"Technologies\":\"Advanced clinical trial methodologies, real-world evidence analysis, and data monitoring systems.\",\"People\":\"Patients receiving COVID-19 treatment, especially those administered with investigational drugs like tocilizumab and ACE2-targeted treatments.\",\"Owner\":\"Healthcare professionals, pharmaceutical companies, regulatory agencies.\"}]}"}}